Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Gastroesophageal Reflux Disease

Gastroesophageal Reflux Disease

Part of Esophageal Diseases

11 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Gastroesophageal Reflux Disease

76 trials tracked for Gastroesophageal Reflux Disease: 35 in phase 3 or 4 and 4 with published results. The most-cited published study has 52 citations.

76Trials tracked
35Phase 3 & 4
0Recruiting
4With published results
Phase distribution
Phase 4 10 Phase 3 25 Phase 2 9 Phase 1 6 Other / NA 26
  1. Phase 3 Gastroesophageal Reflux Treatment in Scleroderma Completed · 52 cited
  2. Phase 3 A Double-blind Comparative Study of the Efficacy and Safety of E3810 10mg Once and Twice Daily in Maintenance Therapy for PPI Resistant Gastroesophageal Reflux Disease Patients Completed · 30 cited
  3. Phase 3 Compound Sodium Alginate Double Action Chewable Tablet Symptomatic Relief Study Completed · 28 cited
  4. Phase 4 Pharmacokinetics of Immediate-Release vs. Delayed-Release Omeprazole in Gastroparesis Completed · 4 cited
  5. Phase 4 Do Laryngeal Tissue Changes in Patients Suspected of Having Laryngopharyngeal Reflux Predict Response to Treatment? Completed
  6. Phase 4 Dexlansoprazole in Asian Participants With Gastroesophageal Reflux Disease Completed
Show 44 more trials
  1. Phase 4 Implementation of PPI Medication PGX Testing Completed
  2. Phase 4 Phase IV Study of the Impact of Dietary Fibers on Symptoms and Esophageal Motility in Patients With Non-erosive GERD Completed
  3. Phase 4 Role of Pepsin Assay in Wheezy Infants Completed
  4. Phase 4 Safety and Efficacy of Lansoprazole in Patients With Reflux Disease Completed
  5. Phase 4 Local Phase IV, Gastroesophageal Reflux Disease (GERD) Sleep Study US Completed
  6. Phase 4 To Assess the Efficacy of Esomeprazole 20mg Once Daily in Subjects Who Still Had Heartburn After Receiving Rabeprazole Completed
  7. Phase 4 A Study of Nexium (Esomeprazole) 40 mg Once Daily in Subjects With Symptoms of Gastroesophageal Reflux Disease (GORD) After Treatment With a Full Dose of Proton Pump Inhibitor (PPI) Completed
  8. Phase 3 Efficacy and Safety of Dexlansoprazole on Heartburn Relief in Chinese Patients Completed
  9. Phase 3 Compound Sodium Alginate Double Action Chewable Tablets 4-hour Esophageal pH Study in GERD Patients Completed
  10. Phase 3 Genotype-tailored Treatment of Symptomatic Acid-Reflux in Children With Uncontrolled Asthma Completed
  11. Phase 3 Safety and Efficacy of Dexlansoprazole Modified Release Formulation to Treat Heartburn Completed
  12. Phase 3 Efficacy of Dexlansoprazole MR on Heartburn Control in Participants Previously Receiving Twice Daily Proton Pump Inhibitor Therapy Completed
  13. Phase 3 Study Evaluating Pantoprazole in Children With GERD Completed
  14. Phase 3 A Study of Dexlansoprazole Modified Release Formulation to Treat Night Heartburn Completed
  15. Phase 3 Medical Treatment for Gastroesophageal Reflux Disease (GERD) in Preterm Infants Completed
  16. Phase 3 Phase III Study Comparing Zegerid® With Losec® for the Relief of Heartburn Associated With Gastroesophageal Reflux Disease Completed
  17. Phase 3 The Role Of Gastroesophageal Reflux Disease (GERD) in Eosinophilic Esophagitis Completed
  18. Phase 3 Study Evaluating the Efficacy and Safety of Pantoprazole in Infants With Symptomatic Gastroesophageal Reflux Disease (GERD) Completed
  19. Phase 3 Safety and Efficacy Study of Axid Use in Infants Suffering From Gastroesophageal Reflux Disease (GERD) Completed
  20. Phase 3 Esomeprazole (NEXIUM) vs. Surgery Completed
  21. Phase 3 Study Evaluating Pantoprazole in Children With Gastroesophageal Reflux Disease (GERD) Completed
  22. Phase 3 Safety and Efficacy of Dexlansoprazole Modified Release Formulation to Treat Gastroesophageal Reflux Disease Completed
  23. Phase 3 Study Evaluating Pantoprazole Sodium Enteric-Coated Spheroid Suspension In Infants With Presumed GERD Completed
  24. Phase 3 Safety and Efficacy of Rabeprazole in Infants With Gastroesophageal Erosive Reflux Disease (GERD) Completed
  25. Phase 3 Open Label Safety Study of Enteric-Coated Spheroid Suspension in Infants Aged Less Than 12 Months With Presumed Gastroesophageal Reflux Disease (GERD) Completed
  26. Phase 3 Safety and Quality of Life Study of Dexlansoprazole Modified Release Formulation to Treat Heartburn Completed
  27. Phase 3 Role of Pain Modulation in GERD Patients Who Failed Standard Dose PPI Completed
  28. Phase 3 Efficacy and Safety of Dexlansoprazole Modified Release Formulation to Treat Heartburn Completed
  29. Phase 3 Study Evaluating Pantoprazole in Neonates and Preterm Infants With GERD Completed
  30. Phase 2 Maintenance Intermittent Therapy for Symptomatic GERD Patients Completed
  31. Phase 2 Comparison of Vonoprazan to Esomeprazole in Participants With Symptomatic GERD Who Responded Partially to a High Dose of Proton Pump Inhibitor (PPI) Completed
  32. Phase 2 Treatment of Gastroesophageal Reflux Disease in 12-16 Year Old Patients With Rabeprazole Completed
  33. Phase 2 Safety and Efficacy of Dexlansoprazole Delayed-Release Capsules for Healing of Erosive Esophagitis and Maintenance of Healed Erosive Esophagitis and Relief of Heartburn in Adolescents Completed
  34. Phase 2 A Study to Estimate Effect of 4 Different Doses of AZD3355 on Reflux Episodes, Which Patients With Gastroesophageal Reflux Disease (GERD) May Experience Completed
  35. Phase 2 Investigate the Effect of Different Doses of Lesogaberan (AZD3355) as add-on to PPI in GERD Patients With Partial Response to PPI Completed
  36. Phase 2 Safety and Efficacy of Dexlansoprazole Delayed-Release Capsules in Treating Symptomatic Non-Erosive Gastroesophageal Reflux Disease in Adolescents Completed
  37. Phase 2 A Trial of IW-3718 for 8 Weeks in Patients With Symptomatic Gastroesophageal Reflux Disease (GERD) Completed
  38. Phase 2 Selective 5-HT4 Receptor Agonist and Proton Pump Inhibitor (PPI) in Subjects With Gastroesophageal Reflux Disease (GERD) Completed
  39. Phase 1 A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Vonoprazan in Adolescents With Symptomatic Gastroesophageal Reflux Disease Completed
  40. Phase 1 Pharmacokinetic and Safety of Dexlansoprazole in Adolescents With Gastroesophageal Reflux Disease Completed
  41. Phase 1 Sensory Evaluation of Dexlansoprazole Delayed-Release Orally Disintegrating Tablets Completed
  42. Phase 1 Study to Evaluate the Pharmacokinetics and Safety of Dexlansoprazole in Pediatric Subjects With Symptomatic Gastroesophageal Reflux Disease Completed
  43. Phase 1 PK Study With Pantoprazole in Obese Children and Adolescents Completed
  44. Phase 1 A Study to Evaluate Vonoprazan in Children Who Have Symptomatic Gastroesophageal Reflux Disease Completed

Showing the 50 most-cited and recently-updated of 76 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Gastroesophageal Reflux Disease: what the trials found

Several proton pump inhibitors (PPIs) have demonstrated efficacy in managing GERD symptoms and physiological markers. Esomeprazole significantly reduced the frequency of heartburn over 8 weeks 9 and showed improvements in sleep quality, with a reduction in mean Pittsburgh Sleep Quality Index scores and resolution of sleep disturbances associated with GERD 7. Rabeprazole was shown to improve daytime and nighttime heartburn as well as acid regurgitation 17, while also demonstrating significant rates of non-recurrence over 52 weeks 12.

Specific formulations and adjuncts show varying impacts on reflux metrics. Mucofalk significantly reduced the number of gastroesophageal refluxes 3 and the number of acid gastroesophageal refluxes 3. Sodium alginate double action chewable tablets significantly improved scores across multiple dimensions, including GERD, dyspepsia, and heartburn 13, while also reducing the duration and frequency of esophageal pH levels below 4 or 5 15. Dexlansoprazole showed varying results in NERD and EE populations regarding heartburn-free days 5 and specific counts of nighttime heartburn-free days 16.

Other interventions include immediate-release omeprazole 1, the combination of omeprazole and domperidone 2, and metaclopramide 18. Clinical assessments with lansoprazole showed no significant change in GERD symptom assessment scores (GSAS) or asthma control over 26 weeks 14. Long-term data for esomeprazole indicates a low rate of treatment failure at 5 years 22.

For the clinician treating this condition

  • Esomeprazole is effective in reducing heartburn frequency and improving sleep quality in patients with GERD-related sleep disturbances.
  • Rabeprazole shows significant efficacy in reducing both daytime and nighttime heartburn symptoms and acid regurgitation.
  • Sodium alginate double action chewable tablets provide statistically significant improvements in multiple dimensions of reflux and dyspepsia while maintaining higher esophageal pH levels.

AI synthesis of 14 cited trials, updated Jun 26, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Pediatric GERD and proton pump inhibitor exposure are associated with reduced microbial diversity
Gastroenterology Meta-analysis
Pediatric GERD and proton pump inhibitor exposure are associated with reduced microbial diversity Proton Pump Inhibitors Linked to Changes in Childrens Gut Health
This systematic review of 31 studies examines the impact of gastroesophageal reflux disease (GERD) and proton pump inhibitor (PPI) use on th…
New research suggests that proton pump inhibitors for childhood reflux may lead to less diverse gut bacteria and other changes in the microb…
Frontiers Aug 22, 2026
Vonoprazan therapy associated with anaphylaxis in a patient with pollen-food allergy syndrome
Allergy & Immunology Guideline
Vonoprazan therapy associated with anaphylaxis in a patient with pollen-food allergy syndrome Acid reflux medication linked to severe soy allergy reactions
This case report describes a 59-year-old woman who experienced two episodes of anaphylaxis after consuming soy products while receiving vono…
A woman experienced life-threatening allergic reactions after taking a specific acid reflux medication while consuming soy products.
Frontiers Aug 18, 2026
Lifestyle modification and optimized proton pump inhibitor therapy are first-line treatments for gastroesophageal reflux disease
Rheumatology Guideline
Lifestyle modification and optimized proton pump inhibitor therapy are first-line treatments for gastroesophageal reflux disease New guidelines offer clearer paths for managing acid reflux disease
This clinical guideline provides standardized management protocols for patients with gastroesophageal reflux disease in Vietnam. It emphasiz…
New clinical guidelines provide a standardized roadmap for diagnosing and treating acid reflux and esophageal inflammation in Vietnam.
Frontiers Aug 16, 2026
Banxia Xiexin Tang may modulate inflammatory signaling and oxidative stress in gastric cardia cancer models
Drug Pipeline Meta-analysis
Banxia Xiexin Tang may modulate inflammatory signaling and oxidative stress in gastric cardia cancer models Banxia Xiexin Tang May Help Manage Gastric Cardia Cancer Symptoms
This narrative review explores the role of Banxia Xiexin Tang (BXT) in managing gastric cardia cancer and related conditions like gastritis.…
New research suggests the herbal formula Banxia Xiexin Tang may reduce inflammation and oxidative stress in patients with gastric cardia can…
Frontiers Jun 20, 2026
Patient- and GP-facing deprescribing intervention increases PPI dose reduction by 6.9% in adults with chronic PPI use
Primary Care & Family Medicine RCT
Patient- and GP-facing deprescribing intervention increases PPI dose reduction by 6.9% in adults with chronic PPI use Combining patient education with doctor letters cuts acid reflux drug use by nearly 7 percent
This cluster randomized clinical trial evaluated a deprescribing intervention in 1498 general practitioners and 34 409 patients across weste…
A new trial shows that giving patients information and doctors a clear plan helps reduce unnecessary acid reflux medication use in adults.
Jun 1, 2026
Meta-analysis compares total vs partial fundoplication for pediatric GERD
Pediatrics Meta-analysis
Meta-analysis compares total vs partial fundoplication for pediatric GERD Partial Fundoplication Lowers Dysphagia Risk in Children with GERD
This meta-analysis of 2633 patients younger than 18 years with GERD found that total fundoplication (Nissen) was associated with a higher ri…
In children with GERD, partial fundoplication reduces postoperative swallowing problems compared to total fundoplication, while reflux contr…
May 6, 2026
GERD Associated with Increased Risk of Laryngeal Cancer in Meta-Analysis
ENT (Otolaryngology) Meta-analysis
GERD Associated with Increased Risk of Laryngeal Cancer in Meta-Analysis Large study links GERD to higher risk of laryngeal cancer
A systematic review and meta-analysis of 1,768,394 adults found that gastroesophageal reflux disease (GERD) was significantly associated wit…
A massive analysis of nearly 1.8 million adults found a link between gastroesophageal reflux disease and increased risk of laryngeal cancer.
May 1, 2026
Systematic review and meta-analysis finds elevated magnetic sphincter augmentation erosion after sleeve gastrectomy
Diabetes & Endocrinology Meta-analysis
Systematic review and meta-analysis finds elevated magnetic sphincter augmentation erosion after sleeve gastrectomy Magnetic sphincter augmentation erosion risk is higher after sleeve gastrectomy
This systematic review and meta-analysis of 287 patients found that magnetic sphincter augmentation (MSA) erosion after laparoscopic sleeve …
A meta-analysis shows patients with sleeve gastrectomy have a higher erosion rate after magnetic sphincter augmentation compared to nonbaria…
May 1, 2026
Zinc-L-carnosine supplement versus thickened formula for persistent infant regurgitation in randomized trial
Pediatrics RCT
Zinc-L-carnosine supplement versus thickened formula for persistent infant regurgitation in randomized trial Thickened Formula May Cost More Than This New Supplement
A two-center, prospective, single-blind, randomized, non-inferiority study evaluated Zinc-L-carnosine in 60 infants aged 4 weeks to 7 months…
A new baby supplement for spit-up costs less and works as well as the expensive thickened formula parents often use.
Frontiers Apr 21, 2026
PPI-refractory GERD prevalence and mechanisms in systemic sclerosis using ambulatory pH-MII, HREM, and scintigraphy
Rheumatology Cohort
PPI-refractory GERD prevalence and mechanisms in systemic sclerosis using ambulatory pH-MII, HREM, and scintigraphy Heartburn Pills Often Fail in Scleroderma—New Study Reveals Why
This retrospective cohort study of 30 adults with systemic sclerosis evaluated PPI-refractory GERD using ambulatory pH-MII, HREM, and gastri…
Standard heartburn pills often fail for scleroderma patients because weak muscle movement in the esophagus and stomach prevents acid from cl…
medRxiv Apr 18, 2026
Sleeve-fundoplication without gastric resection reduces GERD incidence versus sleeve gastrectomy in obese rat model
Anesthesiology & Pain Medicine RCT
Sleeve-fundoplication without gastric resection reduces GERD incidence versus sleeve gastrectomy in obese rat model New stomach surgery stops acid burn while you lose weight
A preclinical randomized controlled trial in 24 obese rats found sleeve-fundoplication without gastric resection (SG-F) significantly reduce…
A new stomach surgery helps you lose weight without worsening acid reflux, offering a safer alternative to standard procedures that often ma…
Frontiers Apr 11, 2026

Questions about Gastroesophageal Reflux Disease

Why do some adults with systemic sclerosis still have GERD despite taking acid reducers?

Adults with systemic sclerosis often have reflux that acid reducers cannot stop because their esophagus and stomach muscles do not squeeze properly, causing acid to linger longer in the body.

Full answer →
Can magnetic sphincter augmentation devices erode after sleeve gastrectomy surgery for GERD?

Yes, magnetic sphincter augmentation devices can erode after sleeve gastrectomy, with a significantly higher erosion rate (3.8%) compared to non-bariatric populations (0.1%-0.3%).

Full answer →